Deep neural network classification based on somatic mutations potentially predicts clinical benefit of immune checkpoint blockade in lung adenocarcinoma

References

• Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F, Finley G. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378:2288–13. doi:10.1056/NEJMoa1716948.
   PubMed Web of Science ®Google Scholar
• Lemery S, Keegan P, Pazdur R. First FDA approval agnostic of cancer site when a biomarker defines the indication. N Engl J Med. 2017;377:1409–1412. doi:10.1056/NEJMp1709968.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. The New England Journal of Medicine. 2012;366:2443–2454. doi:10.1056/NEJMoa1200690.
   PubMed Web of Science ®Google Scholar
• Wei SC, Levine JH, Cogdill AP, Zhao Y, Anang NAS, Andrews MC, Sharma P, Wang J, Wargo JA, Pe’er D, et al. Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade. Cell. 2017;170:1120–33.e17. doi:10.1016/j.cell.2017.07.024.
   PubMed Web of Science ®Google Scholar
• Diem S, Hasan Ali O, Ackermann CJ, Bomze D, Koelzer VH, Jochum W, Speiser, D.E., Mertz, K.D. and Flatz, L. Tumor infiltrating lymphocytes in lymph node metastases of stage III melanoma correspond to response and survival in nine patients treated with ipilimumab at the time of stage IV disease. Cancer Immunol Immunother. 2018;67:39–45. doi:10.1007/s00262-017-2061-4.
   PubMed Web of Science ®Google Scholar
• Peng J, Xiao L-S, Dong Z-Y, Li -W-W, Wang K-Y, Wu D-H, Liu L. Potential predictive value of JAK2 expression for pan-cancer response to PD-1 blockade immunotherapy. Transl Cancer Res. 2018;7:462–471. doi:10.21037/tcr.2018.04.09.
   Web of Science ®Google Scholar
• Brahmer JR, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, Gottfried M, Peled N, Tafreshi A, Cuffe S, et al. Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial. Lancet Oncol. 2017;18:1600–1609. doi:10.1016/S1470-2045(17)30690-3.
   PubMed Web of Science ®Google Scholar
• Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, Albright A, Cheng JD, Kang SP, Shankaran V, et al. IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017;127:2930–2940. doi:10.1172/JCI91190.
   PubMed Web of Science ®Google Scholar
• Samstein RMA-O, Lee CH, Shoushtari ANA-O, Hellmann MDA-O, Shen R, Janjigian YY, Barron, D.A., Zehir, A., Jordan, E.J., Omuro, A, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019;51:202–206. doi:10.1038/s41588-018-0312-8.
   PubMed Web of Science ®Google Scholar
• Miao D, Margolis CA, Vokes NI, Liu D, Taylor-Weiner A, Wankowicz SM, Adeegbe D, Keliher D, Schilling B, Tracy A, et al. Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. Nat Genet. 2018;50:1271–1281. doi:10.1038/s41588-018-0200-2.
   PubMed Web of Science ®Google Scholar
• Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348:124–128. doi:10.1126/science.aaa1348.
   PubMed Web of Science ®Google Scholar
• Biton J, Mansuet-Lupo A, Pecuchet N, Alifano M, Ouakrim H, Arrondeau J, Boudou-Rouquette P, Goldwasser F, Leroy K, Goc J, et al. TP53, STK11, and EGFR mutations predict tumor immune profile and the response to anti-PD-1 in lung adenocarcinoma. Clin Cancer Res. 2018;24:5710–5723. doi:10.1158/1078-0432.CCR-18-0163.
   PubMed Web of Science ®Google Scholar
• Kato S, Goodman A, Walavalkar V, Barkauskas DA, Sharabi A, Kurzrock R. Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate. Clin Cancer Res. 2017;23:4242–4250. doi:10.1158/1078-0432.CCR-16-3133.
   PubMed Web of Science ®Google Scholar
• Skoulidis F, Goldberg MEA-O, Greenawalt DM, Hellmann MD, Awad MM, Gainor JF, Schrock AB, Hartmaier RJ, Trabucco SE, Gay L, et al. STK11/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma. Cancer Discov. 2018;8:822–835. doi:10.1158/2159-8290.CD-18-0099.
   PubMed Web of Science ®Google Scholar
• Dong ZY, Zhong WZ, Zhang XC, Su J, Xie Z, Liu SY, Tu HY, Chen HJ, Sun YL, Zhou Q, et al. Potential predictive value of TP53 and KRAS mutation status for response to PD-1 blockade immunotherapy in lung adenocarcinoma. Clin Cancer Res. 2017;23:3012–3024. doi:10.1158/1078-0432.CCR-16-2554.
   PubMed Web of Science ®Google Scholar
• Wang Z, Zhao J, Wang G, Zhang F, Zhang Y, Dong H, Zhao X, Duan J, Bai H, Tian Y, et al. Comutations in DNA damage response pathways serve as potential biomarkers for immune checkpoint blockade. Cancer Res. 2018;78:6486–6496. doi:10.1158/0008-5472.CAN-18-1814.
   PubMed Web of Science ®Google Scholar
• Zehir AA-O, Benayed R, Shah RH, Syed A, Middha SA-O, Kim HRA-O, Srinivasan P, Gao J, Chakravarty D, Devlin SM, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2017;23:703–713. doi:10.1038/nm.4333.
   PubMed Web of Science ®Google Scholar
• Kermany DS, Goldbaum M, Cai W, Valentim CCS, Liang H, Baxter SL, McKeown, A., Yang, G., Wu, X., Yan, F, et al. Identifying medical diagnoses and treatable diseases by image-based deep learning. Cell. 2018;172:1122–31.e9. doi:10.1016/j.cell.2018.02.010.
   PubMed Web of Science ®Google Scholar
• Chaudhary K, Poirion OB, Lu L, Garmire LX. Deep learning-based multi-omics integration robustly predicts survival in liver cancer. Clin Cancer Res. 2018;24:1248–1259. doi:10.1158/1078-0432.CCR-17-0853.
   PubMed Web of Science ®Google Scholar
• Rizvi H, Sanchez-Vega F, La K, Chatila W, Jonsson P, Halpenny D, Plodkowski A, Long N, Sauter JL, Rekhtman N, et al. Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing. J Clin Oncol. 2018;36:633–641. doi:10.1200/JCO.2017.75.3384.
   PubMed Web of Science ®Google Scholar
• Newman AM, Liu CL, Green MA-O, Gentles AA-O, Feng W, Xu Y, Hoang, C.D., Diehn, M. and Alizadeh, A.A. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12:453–457. doi:10.1038/nmeth.3337.
   PubMed Web of Science ®Google Scholar
• Charoentong P, Finotello F, Angelova M, Mayer C, Efremova M, Rieder D, Hackl, H. and Trajanoski, Z. Pan-cancer immunogenomic analyzes reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. 2017;18:248–262. doi:10.1016/j.celrep.2016.12.019.
   PubMed Web of Science ®Google Scholar
• Peng J, Zhang J, Zhang Q, Xu Y, Zhou J, Liu L. A radiomics nomogram for preoperative prediction of microvascular invasion risk in hepatitis B virus-related hepatocellular carcinoma. Diagn Interv Radiol. 2018;24:121–127. doi:10.5152/dir.
   PubMed Web of Science ®Google Scholar
• Hyman DM, Piha-Paul SA, Won H, Rodon J, Saura C, Shapiro GI, Juric, D., Quinn, D.I., Moreno, V., Doger, B, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature. 2018;554:189–194. doi:10.1038/nature25475.
   PubMed Web of Science ®Google Scholar
• Harding JJ, Nandakumar S, Armenia J, Khalil DN, Albano M, Ly M, Shia J, Hechtman JF, Kundra R, El Dika I,.et al. Prospective genotyping of hepatocellular carcinoma: clinical implications of next-generation sequencing for matching patients to targeted and immune therapies. Clin Cancer Res. 2019;25:2116–2126. doi:10.1158/1078-0432.CCR-18-2293.
   PubMed Web of Science ®Google Scholar
• Campbell JA-O, Alexandrov AA-O, Kim J, Wala J, Berger AH, Pedamallu CA-OX, Shukla SA, Guo G, Brooks AN, Murray BA, et al. Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. Nat Genet. 2016;48:607–616. doi:10.1038/ng.3564.
   PubMed Web of Science ®Google Scholar
• Yarchoan M, Albacker LA, Hopkins AC, Montesion M, Murugesan K, Vithayathil TT, Zaidi N, Azad NS, Laheru DA, Frampton GM, et al. PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers. JCI Insight. 2019;4:e126908. doi:10.1172/jci.insight.126908.
   PubMed Web of Science ®Google Scholar
• Wang Z, Duan J, Cai S, Han M, Dong H, Zhao J, Zhu B, Wang S, Zhuo M, Sun J, et al. Assessment of blood tumor mutational burden as a potential biomarker for immunotherapy in patients with non-small cell lung cancer with use of a next-generation sequencing cancer gene panel. JAMA Oncol. 2019. Epub ahead of print. doi:10.1001/jamaoncol.2018.
   Web of Science ®Google Scholar
• Ricciuti B, Kravets S, Dahlberg SE, Umeton R, Albayrak A, Subegdjo SJ, Johnson BE, Nishino M, Sholl LM, Awad MM. Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer. J Immunother Cancer. 2019;7:87. doi:10.1186/s40425-019-0572-6.
   PubMed Web of Science ®Google Scholar
• Goodman AM, Kato S, Bazhenova L, Patel SP, Frampton GM, Miller V, Stephens PJ, Daniels GA, Kurzrock R. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol Cancer Ther. 2017;16:2598–2608. doi:10.1158/1535-7163.MCT-17-0386.
   PubMed Web of Science ®Google Scholar
• Ock CY, Keam B, Kim S, Lee JS, Kim M, Kim TM, Jeon YK, Kim DW, Chung DH, Heo DS. Pan-cancer immunogenomic perspective on the tumor microenvironment based on PD-L1 and CD8 T-cell infiltration. Clin Cancer Res. 2016;22:2261–2270. doi:10.1158/1078-0432.CCR-15-2834.
   PubMed Web of Science ®Google Scholar
• Chen YP, Zhang Y, Lv JW, Li YQ, Wang YQ, He QM, Yang XJ, Sun Y, Mao YP, Yun JP, et al. Genomic analysis of tumor microenvironment immune types across 14 solid cancer types: immunotherapeutic implications. Theranostics. 2017;7:3585–3594. doi:10.7150/thno.21471.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387:1540–1550. doi:10.1016/S0140-6736(15)01281-7.
   PubMed Web of Science ®Google Scholar
• Dhupkar P, Gordon N, Stewart J, Kleinerman ES. Anti-PD-1 therapy redirects macrophages from an M2 to an M1 phenotype inducing regression of OS lung metastases. Cancer Med. 2018;7:2654–2664. doi:10.1002/cam4.2018.7.issue-6.
   PubMed Web of Science ®Google Scholar
• Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541:321–330. doi:10.1038/nature21349.
   PubMed Web of Science ®Google Scholar
• Skoulidis F, Byers LA, Diao L, Papadimitrakopoulou VA, Tong P, Izzo J, Behrens C, Kadara H, Parra ER, Canales JR, et al. Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. Cancer Discov. 2015;5:860–877. doi:10.1158/2159-8290.CD-14-1236.
   PubMed Web of Science ®Google Scholar
• Ott PA, Bang YJ, Piha-Paul SA, Razak ARA, Bennouna J, Soria JC, Rugo HS, Cohen RB, O’Neil BH, Mehnert J, et al. T-cell-inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028. J Clin Oncol. 2019;37:318–327. doi:10.1200/JCO.2018.78.2276.
   PubMed Web of Science ®Google Scholar
• Cristescu RA-O, Mogg R, Ayers M, Albright A, Murphy E, Yearley J, Sher X, Liu XQ, Lu H, Nebozhyn M, et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science. 2018;362:eaar3593. doi:10.1126/science.aar3593.
   PubMed Web of Science ®Google Scholar